RC
VYNE icon

Rangeley Capital’s VYNE Therapeutics VYNE Stock Holding History

Rangeley Capital’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.5K Buy
118,064
+18,064
+18% +$10.5K 0.07% 126
2025
Q4 		$58K Buy
100,000
+50,000
+100% +$20.1K 0.05% 113
2025
Q3 		$16.8K Buy
+50,000
New +$32.7K 0.01% 127

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rangeley Capital's VYNE Position: Q1 2026 in Review

Rangeley Capital increased its VYNE Therapeutics (VYNE) stake by 18% in Q1 2026, buying an estimated $10.5K and bringing the position to 118,064 shares worth $70.5K. The position accounts for 0.07% of the portfolio, ranked #126.

Rangeley Capital first reported a position in VYNE in Q3 2025 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Rangeley Capital held 118,064 shares of VYNE Therapeutics worth $70.5K as of Q1 2026.
  • Rangeley Capital bought 18,064 VYNE Therapeutics shares in Q1 2026, an estimated $10.5K.
  • VYNE Therapeutics made up 0.07% of Rangeley Capital's portfolio in Q1 2026, its #126 holding.
  • Rangeley Capital first reported a position in VYNE Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.